Conference Proceedings

Prostate-specific antigen velocity as a predictive biomarker in a prospective prostate cancer screening study (IMPACT study)

Christos Mikropoulos, Christina Selkirk, Sibel Saya, Elizabeth Bancroft, Tokhir Dadaev, Charles Brendler, Edward Saunders, Daniel Leongamornlert, Elizabeth Page, Clara Cieza Borrella, Sue Moss, Zsofia Kote-Jarai, Brian Helfand, Ros A Eeles

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2015

Abstract

16 Background: We retrospectively assessed the clinical application of Prostate Specific Antigen Velocity (PSA V) in the IMPACT study (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in men at higher genetic risk and controls). This is a case-control prostate cancer (PrCa) screening study for men with a known genetic predisposition to PrCa; participants with a single PSA reading above 3ng/ml are offered diagnostic TRUS prostate biopsies (PB). Methods: We calculated PSA velocity (PSA V) using all three validated methods, including the arithmetic mean, the linear regression and the first and last readings equations. Pearson chi-square test was used t..

View full abstract

University of Melbourne Researchers